适应症:哮喘 9月4日,阿斯利康的AZD8630吸入剂的IND获CDE受理。AZD8630(AMG104)是一款抗胸腺基质淋巴细胞生成素(TSLP) 单克隆抗体,有望实现每日一次吸入。TSLP是一种主要由气道上皮表达的细胞因子,在环境损伤时释放,引发一系列下游炎症过程。有充分...
Together with low rates of immunogenicity following 4-weeks of dosing this data supports the ongoing development of AZD8630/AMG 104 as a first-in-class inhaled biologic treatment option for asthma patients.Sara AsimusWaqas Muhammad SadiqJason Cooper...
There was a statistically significant reduction in FeNO in asthmatics following AZD8630/AMG104 dosing (23% vs placebo, one-sided p-value 0.037). that was evident from day 7 day to the end of the treatment (day 28). Serum IL-5 and -13 showed trends for lower levels following drug ...